Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.

Détails

Ressource 1Télécharger: BIB_0C3DC2A803E0.P001.pdf (2142.91 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_0C3DC2A803E0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.
Périodique
Journal of Biomedicine and Biotechnology
Auteur(s)
Iancu E.M., Baumgaertner P., Wieckowski S., Speiser D.E., Rufer N.
ISSN
1110-7243
1110-7251 (Electronic)
ISSN-L
1110-7243
Statut éditorial
Publié
Date de publication
2011
Volume
2011
Pages
452606
Langue
anglais
Résumé
T-cell vaccination may prevent or treat cancer and infectious diseases, but further progress is required to increase clinical efficacy. Step-by-step improvements of T-cell vaccination in phase I/II clinical studies combined with very detailed analysis of T-cell responses at the single cell level are the strategy of choice for the identification of the most promising vaccine candidates for testing in subsequent large-scale phase III clinical trials. Major aims are to fully identify the most efficient T-cells in anticancer therapy, to characterize their TCRs, and to pinpoint the mechanisms of T-cell recruitment and function in well-defined clinical situations. Here we discuss novel strategies for the assessment of human T-cell responses, revealing in part unprecedented insight into T-cell biology and novel structural principles that govern TCR-pMHC recognition. Together, the described approaches advance our knowledge of T-cell mediated-protection from human diseases.
Mots-clé
Animals, CD8-Positive T-Lymphocytes/cytology, Cancer Vaccines/metabolism, Cell Differentiation, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Gene Expression Profiling, Humans, Immune System, Major Histocompatibility Complex, Melanoma/therapy, Mice, Neoplasms/immunology, Neoplasms/therapy, Phenotype, Receptors, Antigen, T-Cell/metabolism, T-Lymphocytes, Cytotoxic/cytology, T-Lymphocytes, Cytotoxic/immunology
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/02/2011 14:47
Dernière modification de la notice
20/08/2019 12:33
Données d'usage